Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16105676 | 0.85 | CA3 (0.42) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL13403327 | 0.82 | PTGS1 (0.42) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL441530 | 0.80 | ALDH1A1 (0.42) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL13990327 | 0.78 | ALDH1A1 (0.33) | PTGS1PTGS2ALDH1A1ALOX15KDM4E | |
| SCHEMBL10170297 | 0.78 | NR3C1 (0.40) | PTGS1PTGS2ALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL1690352 | 0.78 | ALDH1A1 (0.44) | PTGS1PTGS2ALDH1A1MEN1KMT2A | |
| SCHEMBL6763833 | 0.78 | MAPK1 (0.39) | ALDH1A1MEN1KMT2AALOX15KDM4E | |
| SCHEMBL10183565 | 0.78 | ALDH1A1 (0.43) | CA9ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL20876273 | 0.78 | CA3 (0.37) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL28335458 | 0.78 | CA3 (0.41) | CA3CA6CA5ACA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024106914-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | VORONOI INC. (KR) | 2024-05-23 | — | — | WO | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230329095-A1 | Novel Compound, Coating Composition Comprising Same, Organic Light-Emitting Device Using Same, and Manufacturing Method Therefor | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2023-09-12 | — | — | US | disclosed |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2023-09-12 | — | — | US | disclosed |
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-7235545-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235545-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7217712-B2 | 4-Substituted-5-cyano-1H-pyrimidin-6-(thi)ones as GSK-3 inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-15 | — | — | US | disclosed |
| US-7214668-B2 | Phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CA3 4693/4885CA6 3764/4885CA5A 3334/4885 |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | DHODH, DLD, DPYD | CA3 2817/4885CA6 2112/4885CA5A 374/4885 |
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | CA3 2135/4885CA6 3396/4885CA5A 630/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CA3 4693/4885CA6 3764/4885CA5A 3334/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | CA3 2532/4885CA6 2614/4885CA5A 2103/4885 |
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | CA3 4618/4885CA6 4781/4885CA5A 4360/4885 |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | CA3 3321/4885CA6 4862/4885CA5A 2273/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | CA3 325/4885CA6 2263/4885CA5A 1636/4885 |
| US-20230329095-A1 | Novel Compound, Coating Composition Comprising Same, Organic Light-Emitting Device Using Same, and Manufacturing Method Therefor | NOTUM, OR51E2, ORMDL3 | CA3 4757/4885CA6 2526/4885CA5A 4287/4885 |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | CA3 3886/4885CA6 4795/4885CA5A 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.